{"analyses":[{"groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":">0.05","statisticalMethod":"ANOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.1","value":"-0.04"},{"groupId":"OG001","spread":"0.08","value":"0.02"},{"groupId":"OG002","spread":"0.05","value":"0.04"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"description":"Measured at baseline and after one year at the distal non-dominant antebrachii.","dispersionType":"Standard Error","groups":[{"description":"15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.","id":"OG000","title":"Combined Treatment."},{"description":"16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.","id":"OG001","title":"Denosumab Monotherapy"},{"description":"15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.","id":"OG002","title":"Placebo"}],"paramType":"MEAN","populationDescription":"One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. One participant from the denosumab group experienced a wrist fracture prior to the final scan and was excluded. 4 patients did not provide data for the analysis due to errors in the technique of the obtained images.","reportingStatus":"POSTED","timeFrame":"Baseline, one year.","title":"Change in Cortical Width.","type":"SECONDARY","unitOfMeasure":"mm"}